PicoCELA (NASDAQ:PCLA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of PicoCELA (NASDAQ:PCLA) to a hold rating in a report released on Saturday morning.

Separately, Weiss Ratings raised PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, PicoCELA has an average rating of “Sell”.

PicoCELA Price Performance

Shares of NASDAQ:PCLA opened at $5.00 on Friday. PicoCELA has a 52 week low of $1.35 and a 52 week high of $17.97. The firm has a 50 day moving average of $5.58 and a 200 day moving average of $4.38.

Institutional Investors Weigh In On PicoCELA

An institutional investor recently bought a new stake in PicoCELA stock. XTX Topco Ltd acquired a new stake in shares of PicoCELA Inc. (NASDAQ:PCLA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned approximately 0.16% of PicoCELA as of its most recent SEC filing.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.